Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$25.35 - $31.96 $687,897 - $867,266
-27,136 Reduced 65.97%
14,000 $441,000
Q3 2022

Nov 14, 2022

BUY
$25.5 - $41.42 $1.05 Million - $1.7 Million
41,136 New
41,136 $1.16 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Pura Vida Investments, LLC Portfolio

Follow Pura Vida Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pura Vida Investments, LLC with notifications on news.